Alector to Participate in the BofA Securities 2023 Healthcare Conference
May 02, 2023 07:00 ET
|
Alector, Inc.
SOUTH SAN FRANCISCO, Calif., May 02, 2023 (GLOBE NEWSWIRE) -- Alector, Inc. (Nasdaq: ALEC), a clinical-stage biotechnology company pioneering immuno-neurology, today announced management will...
Alector to Participate in Upcoming Healthcare Conferences
March 01, 2023 16:05 ET
|
Alector, Inc.
SOUTH SAN FRANCISCO, Calif., March 01, 2023 (GLOBE NEWSWIRE) -- Alector, Inc. (Nasdaq: ALEC), a clinical-stage biotechnology company pioneering immuno-neurology, today announced that management will...
Alector Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Corporate Update
February 28, 2023 16:05 ET
|
Alector, Inc.
On track to complete enrollment in the INVOKE-2 Phase 2 clinical trial of AL002 in patients with early Alzheimer’s disease in Q3 2023, with data readout expected by Q4 2024 Preparing to engage...
Alector Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
December 08, 2022 16:30 ET
|
Alector, Inc.
SOUTH SAN FRANCISCO, Calif., Dec. 08, 2022 (GLOBE NEWSWIRE) -- Alector, Inc. (Nasdaq: ALEC), a clinical-stage biotechnology company pioneering immuno-neurology and innate immuno-oncology, today...
Alector Presents Results from First-in-Human Phase 1 Study of AL101 for the Treatment of Neurodegenerative Diseases
November 29, 2022 11:05 ET
|
Alector, Inc.
AL101 is being developed to elevate progranulin (PGRN) levels with dosing regimens to be optimized for larger indications such as Alzheimer’s disease Study results in healthy volunteers demonstrated...
Alector Reports Third Quarter 2022 Financial Results and Provides Business Update
November 08, 2022 16:05 ET
|
Alector, Inc.
Progressing enrollment in the INFRONT-3 Phase 3 pivotal study for latozinemab (AL001) and in the INVOKE-2 Phase 2 study for AL002 Initiated first-in-human Phase 1 trial of AL044, the company’s third...
Alector to Participate in Upcoming Healthcare Conferences
November 07, 2022 07:00 ET
|
Alector, Inc.
SOUTH SAN FRANCISCO, Calif., Nov. 07, 2022 (GLOBE NEWSWIRE) -- Alector, Inc. (Nasdaq: ALEC), a clinical-stage biotechnology company pioneering immuno-neurology and innate immuno-oncology, today...
Alector Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
November 03, 2022 16:30 ET
|
Alector, Inc.
SOUTH SAN FRANCISCO, Calif., Nov. 03, 2022 (GLOBE NEWSWIRE) -- Alector, Inc. (Nasdaq: ALEC), a clinical-stage biotechnology company pioneering immuno-neurology and innate immuno-oncology, today...
Alector Announces Promotion of Clare Hunt to Chief People Officer
October 13, 2022 08:00 ET
|
Alector, Inc.
Promotion demonstrates Alector’s commitment to building a world-class culture that questions convention, embraces feedback and promotes development for all employees Company recently earned...
Alector Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
October 06, 2022 16:30 ET
|
Alector, Inc.
SOUTH SAN FRANCISCO, Calif., Oct. 06, 2022 (GLOBE NEWSWIRE) -- Alector, Inc. (Nasdaq: ALEC), a clinical-stage biotechnology company pioneering immuno-neurology and innate immuno-oncology, today...